March 21, 2017
On March 20, the Japan International Cooperation Agency (JICA) signed a grant agreement (G/A) with the World Health Organization (WHO) in Kabul to provide grant aid of up to 981 million yen for the Project for Supply of Anti-Tuberculosis Medicines and New Diagnostics Kits and for Monitoring the Implementation of Shorter Multi Drug Resistant Tuberculosis Regimen.
The project has the objectives of procuring anti-tuberculosis medicine and testing equipment needed for the national tuberculosis control program in Afghanistan between 2017 and 2020, and of providing support for measuring and monitoring the effectiveness of the treatment drugs.
Even today, many people in Afghanistan lose their lives to tuberculosis, and in response, the government has established a national tuberculosis control program in the Ministry of Public Health and is advancing measures toward controlling the spread of tuberculosis infections and early eradication. Due to such efforts and cooperation from aid agencies, access to early detection and treatment has improved since 2000, and these collective measures are seeing results, such as an 86.8 percent success rate in the treatment of tuberculosis in 2014. However, the patient detection rate remains a challenge as, according to WHO estimates, there were 60,000 patients and 14,000 deaths in 2016, and there are calls for further efforts toward eradication. Moreover, measures are needed for multidrug-resistant tuberculosis that develops in cases such as when patients do not complete their treatment or the wrong drugs are prescribed as seen in recent years.
The project will procure enough anti-tuberculosis medicine to cure approximately 75,000 drug sensitive tuberculosis patients and 1,000 drug resistant tuberculosis patients, and the testing equipment necessary to test for tuberculosis, making it possible to diagnose and treat tuberculosis infections earlier and with a higher accuracy. Targeting drug-resistant tuberculosis patients who often require long-term conventional tuberculosis treatment and have a low treatment success rate, this project will support activities to supply effective short-term treatment drugs and monitor the treatment effects with those drugs. It is expected that this project will thereby help prevent multidrug-resistant tuberculosis from spreading in Afghanistan, where it is a major challenge.
Through a series of tuberculosis control assistance efforts beginning in 2002, JICA has provided facilities to treat seriously infected patients in isolation and contributed to the stable supply of tuberculosis treatment drugs. Currently, JICA is supporting policy and planning at the Ministry of Public Health, which is in charge of tuberculosis control, and capacity building of medical techniques through the Tuberculosis Control Project in Afghanistan Phase 3, a technical cooperation project.
In cooperation with various partners, including WHO, JICA will continue to provide support to the Government of Afghanistan to control tuberculosis.
|Country||Islamic Republic of Afghanistan|
|Project title||The Project for Supply of Anti-Tuberculosis Medicines and New Diagnostics Kits and for Monitoring the Implementation of Shorter Multi Drug Resistant Tuberculosis Regimen (WHO Partnership)|
|Planned implementation period||46 months|
|Executing agency||World Health Organization, Ministry of Public Health (Afghanistan)|
|Target region, facilities||throughout Afghanistan|
|Specific project details (provisional)||1. Procurement
・ Anti-tuberculosis drugs to treat drug sensitive tuberculosis patients and drug resistant tuberculosis patients
・ Testing equipment to test for tuberculosis
2. Technical support
・ Activities to measure and monitor the effects of short-term treatment drugs for drug resistant tuberculosis